What is BiomX?
BiomX is at the forefront of microbiome therapeutics, specializing in the development of both natural and engineered phage cocktails. These advanced biological agents are designed to precisely target and neutralize harmful bacteria implicated in a range of chronic and debilitating conditions. The company's therapeutic pipeline focuses on diseases such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX's strategic approach involves the discovery and validation of proprietary bacterial targets, followed by the customization of phage compositions to effectively combat these identified pathogens. This data-driven methodology positions BiomX as a key innovator in the burgeoning field of microbiome-based medicine, aiming to address significant unmet medical needs.
How much funding has BiomX raised?
BiomX has raised a total of $71.3M across 4 funding rounds:
Series A
$24M
Series B
$32M
Other Financing Round
$12M
Private Equity
$3.3M
Series A (2017): $24M with participation from OrbiMed, Takeda Ventures, and JJDC
Series B (2019): $32M, investors not publicly disclosed
Other Financing Round (2025): $12M supported by Cystic Fibrosis Foundation
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in BiomX
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development, from early-stage ventures to established organizations scaling proven solutions.
Takeda Ventures
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company, a global, R&D-driven biopharmaceutical leader. They invest in innovative companies that align with Takeda's strategic interests in areas such as oncology, rare diseases, and neuroscience.
JJDC
While the domain suggests an educational institution, in the context of funding, JJDC likely represents a venture capital or investment entity. Further clarification on its specific investment focus would be needed, but its participation indicates a strategic interest in BiomX's development.
What's next for BiomX?
With substantial enterprise-level backing, BiomX is poised for accelerated growth and the advancement of its clinical programs. The recent strategic investment signals strong confidence from investors in the company's innovative phage therapy platform and its potential to disrupt treatment paradigms for chronic diseases. This capital infusion will likely fuel further research and development, expand clinical trial operations, and potentially support the scaling of manufacturing capabilities. BiomX's focus on genetically engineered phages and proprietary bacterial targets suggests a long-term strategy aimed at creating highly specific and effective therapeutic interventions, positioning the company for significant milestones in the coming years.
See full BiomX company page
